Eucrisa carries a retail price of roughly $793 for a single tube, making it one of the pricier prescriptions for a condition as common as eczema. Several factors drive that cost: a billion-dollar corporate acquisition, patent-protected exclusivity, expensive clinical development, and its position as a niche non-steroidal treatment with limited competition.
What Eucrisa Actually Does
Eucrisa (crisaborole) is a topical ointment for mild-to-moderate atopic dermatitis, commonly known as eczema. It works by blocking an enzyme called PDE4, which normally breaks down a molecule that keeps inflammation in check. When PDE4 is blocked, that anti-inflammatory molecule builds up in the skin, calming the overactive immune response that causes eczema flares. The key selling point is that it’s not a steroid. Topical corticosteroids can thin the skin over time, especially on sensitive areas like the face, eyelids, and skin folds. Eucrisa avoids those risks entirely, which makes it appealing for long-term use and for treating areas where steroids are problematic.
That said, Eucrisa is not a particularly potent drug by pharmacological standards. Its binding to PDE4 is over 1,000 times weaker than some other PDE4 inhibitors on the market. It works well enough for mild-to-moderate cases, but it’s not treating severe disease, which makes the high price tag feel especially jarring to patients.
Pfizer Paid $5.2 Billion for the Company Behind It
Eucrisa was originally developed by a small biotech company called Anacor Pharmaceuticals. In May 2016, Pfizer acquired Anacor for approximately $5.2 billion, largely on the strength of crisaborole’s potential. That acquisition cost gets factored into the drug’s pricing. Pfizer needs to recoup a massive investment, and Eucrisa is one of the primary assets that justified the purchase. This is a common pattern in pharmaceuticals: a large company buys a smaller one for a promising pipeline drug, then prices the final product high enough to earn back the acquisition premium plus development costs.
Clinical Trials and FDA Approval Costs
Before reaching the market, Eucrisa went through two large, identically designed clinical trials involving over 1,500 patients across 90 sites. Each trial screened roughly 1,000 patients to enroll 750, accounting for a 33% screening failure rate. These trials compared Eucrisa to a vehicle (essentially the ointment base without the active ingredient) over 28 days of treatment, followed by additional follow-up visits. Running multi-center trials of that size, with the regulatory documentation, site management, and monitoring required for FDA approval, costs hundreds of millions of dollars. Those costs, combined with years of earlier-stage research, all feed into the final price.
Patent Protection Blocks Generic Competition
Eucrisa’s last qualifying patent doesn’t expire until January 2030. Until then, no generic version can legally enter the U.S. market, even though at least five companies have already filed applications to make one. This exclusivity window is the single biggest reason the price stays high. Without competition, Pfizer has no market pressure to lower the cost. Once generics arrive after 2030, the price will likely drop significantly, as it does for most branded drugs that lose patent protection.
How Eucrisa Compares in Cost
The price gap between Eucrisa and traditional eczema treatments is enormous. At about $2.42 per gram, Eucrisa costs roughly 45 times more than generic high-potency corticosteroids like triamcinolone acetonide (about $0.05 per gram) and more than 10 times the cost of generic clobetasol ($0.23 per gram). Even mid-range steroids like mometasone furoate come in at around $0.55 per gram.
Interestingly, Eucrisa is not the most expensive topical option for eczema. Non-steroidal alternatives like tacrolimus ointment run about $3.38 per gram, and pimecrolimus cream costs around $2.91 per gram. These calcineurin inhibitors have been on the market longer but remain comparably expensive because they also occupy a niche as steroid-free options. Eucrisa’s pricing sits squarely in this premium non-steroidal category, competing less on price and more on its distinct mechanism and side-effect profile.
Insurance Often Requires You to Try Cheaper Options First
Most insurance plans don’t cover Eucrisa without prior authorization, and many require step therapy before they’ll approve it. A typical set of requirements, based on state Medicaid criteria, includes trying and failing at least two topical corticosteroids and one calcineurin inhibitor before Eucrisa is approved. Some plans also require that the prescription come from a dermatologist rather than a primary care doctor. Quantity limits are common too: one 60-gram or 100-gram tube per 34 days.
These hurdles exist precisely because Eucrisa is expensive and insurers want patients to use cheaper alternatives first. If you have mild eczema that responds well to a generic steroid cream costing a few dollars, there’s no financial justification for a $793 prescription. The step therapy requirement means Eucrisa is positioned as a second- or third-line treatment for most patients, reserved for cases where cheaper options haven’t worked or can’t be used safely.
Ways to Lower Your Out-of-Pocket Cost
Pfizer offers a patient assistance program for people who are uninsured or underinsured. Uninsured patients can receive 35% to 50% off the retail price regardless of income. For those who qualify based on financial need, eligibility extends to individuals earning up to four times the federal poverty level (roughly $47,000 for a single person or $97,000 for a family of four, though these thresholds adjust over time). Pfizer also periodically offers copay savings cards for commercially insured patients, which can reduce your out-of-pocket cost at the pharmacy.
If you’re paying a significant copay even with insurance, it’s worth asking your dermatologist whether a calcineurin inhibitor like tacrolimus or pimecrolimus would work for your situation. They fill a similar role as non-steroidal alternatives and, depending on your insurance formulary, may have lower copays or fewer prior authorization requirements. For patients who simply need a steroid-free option for sensitive skin areas, those alternatives can be equally effective without the fight to get Eucrisa approved.